Abstract: The present invention provides a human COP9 protein (HuCOP9) and polynucleotides which identify and encode HuCOP9. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of HuCOP9, as well as diagnostic assays.

Abstract: A new human gene termed MCC is disclosed. Antibody based methods and kits are provided for assessing mutations of the MCC gene in human tissues and body samples. Gross rearrangement and point mutations in MCC are observed in human tumor cells. MCC is expressed in most normal tissues. These results suggest that MCC is a tumor suppressor.

Abstract: Infusions of brain-derived neurotrophic factor, neurotrophin-3 or neurotrophin-4 are used to produce analgesia in mammals. In addition, these neurotrophins are used to treat other diseases or disorders mediated by serotonin.

Abstract: The invention provides methods for peripheralizing CD34.sup.+ cells, including hematopoietic stem cells. In a first aspect, the method comprises the step of administering a blocking agent of VLA-4 antigen on the surface of CD34.sup.+ cells. In a second aspect, the method comprises administering a blocking agent of VLA-4 antigen on the surface of CD34.sup.+ cells and administering a stimulating agent of CD34.sup.+ cell proliferation in vivo. The method according to the invention is useful in the treatment of cancer or AIDS, and in gene therapy.

Abstract: The diagnostic interpretation of mammographic films is enhanced by administering to the women undergoing the procedure an effective amount of a gonadotropin releasing hormone antagonist or other inhibitor of ovarian steroid production or action on the breast thereof and effecting the mammogram before the effect of the antagonist or other inhibitor has dissipated.

Abstract: The invention relates to a method of determining the presence of a tyrosine kinase in a sample using antibodies that specifically bind to kinase active proteins. The proteins have more than one tyrosine kinase domain and no SH2 domains. Exemplary proteins are the Janus Kinases, or "JAK1" and "JAK2." Both polyclonal and monoclonal antibodies are used in the detection method.

Abstract: This invention provides a novel gene, OVCA1, isolated from human chromosome 17p13.3. Disruption of the OVCA1 gene is associated with cellular proliferation and tumor development. The OVCA1 gene, along with its encoded protein and antibodies thereto, provides a biological marker for early diagnosis of metastatic disease. The gene also will be useful in gene replacement therapy for treating various forms of cancer.

Abstract: Novel dorsal growth inducing factors, complexes including the factors, and DNA or RNA coding sequences for the factors are described. Hybridoma cell lines and antibodies that bind to the dorsal growth inducing factor noggin, having the amino acid sequence set forth in SEQ ID NO:2, are also described.

Abstract: The present invention provides antibodies capable of discriminating between native human MGMT and an active site alkylated form of this enzyme in an immunoprecipitation procedure.Monoclonal antibodies having such discriminating ability are obtainable from hybridoma ECACC 92112510 and hybridoma ECACC 93112514, which were deposited at the European Collection of Animal Cell Cultures, UK under the Budapest Treaty on 25th Nov. 1992 and 25th Nov. 1993 respectively. The monoclonal antibody of hybridoma ECACC 92112510 has been designated Mab 5H7. The monoclonal antibody of hybridoma ECACC 93112514 has been designated Mab 3C7.

Abstract: Methods of reducing the degeneration of a tissue resulting from mobilization with or without chronic, continuous electrical stimulation by administering basic fibroblast growth factor or heparin to the tissue are provided.

Abstract: A method of testing for the presence of a pathogenic microorganism, notably Salmonella enteritidis, in a foodstuff, e.g. the contents of an egg, or other materials. In a particularly preferred form for testing eggs, the method involves homogenizing a sample of the egg, incubating the egg contents to enrich any pathogen present, adding a detergent to release antigens from pathogen cell surfaces, heating the egg contents to gell them and then carrying out a dot-blot assay of the gelled egg material to detect the presence of the antigens. The method is particularly applicable to D.sub.1 serovars of Salmonella enteritidis. The antibody used in the method is preferably a novel IgG.sub.2.alpha. type immunoglobulin having a lambda light chain, designated as MAb 2F11, which can also be used for other methods of testing for Salmonella enteritidis and other D.sub.1 serovars, and for passive protection of poultry against infections by such pathogens.

Abstract: Peptides derived from prostate specific antigen (PSA) that correspond to the immunodominant epitopes found in the native antigen are disclosed. These peptides were identified using a method that predicts continuous, immunodominant epitopes. Anti-PSA antibodies, methods for their production and their use in diagnostic assays also are disclosed.

Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.

Abstract: An isolated DNA encoding a polypeptide substantially identical to maspin (SEQ ID NO:1); a substantially purified preparation of maspin; an antibody specific for maspin; and use of such DNAs and antibodies in diagnostic, screening, and therapeutic methods.

Abstract: Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

Abstract: A new human gene designated as "CRIPTO" gene has been identified and cloned. CRIPTO gene products and derivatives thereof have been obtained and various utilities of the same have been described. Polyclonal and monoclonal antibodies to the human CRIPTO protein have been described. Association of CRIPTO gene with cancers, such as colorectal cancer and breast carcinoma, has been indicated.

Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human macrophage antigen (TMAH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding TMAH. The invention also provides for the use of substantially purified TMAH and its agonists, antibodies, antagonists or inhibitors in pharmaceutical compositions for treatment of diseases associated with expression of TMAH. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the genomic sequence or transcripts encoding TMAH and anti-TMAH antibodies which specifically bind to TMAH.

Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to "tag" Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.

Abstract: Disclosed are genetic sequences and their encoded amino acid sequences for two interior nuclear matrix proteins useful as markers of malignant cell types. Primary and secondary structure analysis of the proteins is presented as well as means for their recombinant production, and compositions and methods for the use of these markers in clinical assays and cancer therapies.

Abstract: The present invention relates to a monclonal antibody capable of suppressing the motility of cancer cells, a polypeptide recognizable by said anti-cancer antibody and its fragment peptides which is capable of suppressing the motility of cancer cells. The present invention also relates to a production and a use for preventing the matastasis of cancer thereof.